VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues related to the Orphan Drug Tax Credit (no specific bills).
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL MATTOON | — |
| SAMANTHA VENTIMIGLIA | — |
Medicare/Medicaid MMM
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT BARNES | — |
| MICHAEL MATTOON | — |
| SAMANTHA VENTIMIGLIA | — |
Health Issues HCR
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT BARNES | — |
| MICHAEL MATTOON | — |
| SAMANTHA VENTIMIGLIA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.